Liposomal Amphotericin B: 3 mg/kg

Liposomal Amphotericin B: 9 mg/kg

Voriconazole: 400 mg

Total

Sex: Female, Male

Region of Enrollment

Endpoint was whether participant had an invasive fungal infection or not, a potentially fatal complication with leukemia patients. Efficacy defined as absence of proven and probable fungal infection. Probable fungal infection is: 1) Positive radiographic findings consistent with fungal infections documented on CT imaging: Lower respiratory tract infection: halo sign, air crescent-sign, or cavity within areas of consolidation; Sinus: erosion of sinus walls or extension of infection to neighboring structures, extensive skull base destruction; and/or 2) Two positive galactomannan index test.

Number of Participants With Invasive Fungal Infection

Overall Study

Jorge Cortes, MD / Professor

Acute Myelogenous Leukemia

Myelodysplastic Syndrome

400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily

Voriconazole

3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes

Liposomal amphotericin B

9 mg/kg intravenously once per week over 2 hours +/- 15 minutes

The University of Texas M D Anderson Cancer Center

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

Open, Randomized Comparative Trial of Two Different Schedules of Liposomal Amphotericin B Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

M.D. Anderson Cancer Center

blood samples, cells (fibroblasts) from skin biopsy tissue, DNA, urine and stool

sterol/qızdırma

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası